Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : NIFTY NINE IN NINETY NINE PLUS ONE -- Ignore unavailable to you. Want to Upgrade?

To: Scott H. Davis who wrote (499)	4/20/1999 1:10:00 AM
From: WWS	Respond to of 613

Scott, my post was a play on words. Lipids are organic fats (a.k.a., "oils") which can be conjugated with certain drugs to form liposomes that increase the effective half-life of the drug's action in vivo. So, oils combine w/biotech in a metaphorical way only, not in actuality, in companies like LIPO and NXTR that specialize in liposomes. But, an oil company buying a biotech doesn't sound like a bad idea, at least from the perspective of a typical cash-poor biotech.